<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582097</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL 65</org_study_id>
    <nct_id>NCT04582097</nct_id>
  </id_info>
  <brief_title>Ramipril in Pediatric Patients on Hemodialysis</brief_title>
  <official_title>Impact of Angiotensin-converting Enzyme Inhibitor on Pediatric Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of Ramipril in pediatric patients on regular&#xD;
      hemodilaysis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the effect of Ramipril on blood pressure, heart rate, Endothelial dysfunction and&#xD;
      inflammatory markers in pediatric patients on regular hemodilaysis and the correlation of&#xD;
      response with ACE I/D polymorphisms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Actual">February 28, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>concentration of Asymmetric dimethylarginine (ADMA)</measure>
    <time_frame>16 weeks</time_frame>
    <description>marker of endothelial dysfunction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration of high-sensitivity C-reactive protein (Hs-CRP )</measure>
    <time_frame>16 weeks</time_frame>
    <description>marker of inflammation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril, 2.5 mg daily, administered orally for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, matched for the interventional drug, administered orally, daily for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>angiotensin-converting enzyme inhibitor</description>
    <arm_group_label>Ramipril</arm_group_label>
    <other_name>Tritace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>same odor, color and size as the drug but without the active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 16 years old&#xD;
&#xD;
          -  Patients who have been on regular HD for 6 months or longer&#xD;
&#xD;
          -  Hypertension at enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of active connective tissue disease&#xD;
&#xD;
          -  Acute infection within 1 month prior to the study&#xD;
&#xD;
          -  Advanced liver disease&#xD;
&#xD;
          -  Gastrointestinal dysfunction requiring parental nutrition or active malignancy&#xD;
&#xD;
          -  Use of medications such as immunosuppressive drugs within 1 month prior to the study&#xD;
&#xD;
          -  Use of anti-inflammatory medications&#xD;
&#xD;
          -  Use of vitamin E at a dose higher than 60 IU per day or vitamin C higher than 500 mg&#xD;
             per day&#xD;
&#xD;
          -  History of myocardial infarction or cerebrovascular event within 3 months prior to the&#xD;
             study&#xD;
&#xD;
          -  History of ACE inhibitor-associated angioedema&#xD;
&#xD;
          -  Inability to discontinue ACE inhibitors or ARBs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ain Sh University</last_name>
    <role>Principal Investigator</role>
    <affiliation>university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams University Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>October 10, 2020</last_update_submitted>
  <last_update_submitted_qc>October 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Areej Mohamed Ateya</investigator_full_name>
    <investigator_title>Assisstant lecturer</investigator_title>
  </responsible_party>
  <keyword>angiotensin-convertting enzyme inhibitor</keyword>
  <keyword>ramipril</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

